Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
NCT02733445 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2650
Last updated 2016-04-11
Summary
The purpose of this study was to determine how often and how likely patients are to develop Type 2 Diabetes or high cholesterol/lipids when receiving dasatinib or nilotinib as therapy for Chronic Myelogenous Leukemia (CML).
Conditions
- Chronic Myeloid Leukemia (CML)
Interventions
- DRUG
- DRUG
-
nilotinib
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-12-31
- Primary Completion
- 2015-12-31
- Completion
- 2016-03-31
More Related Trials
-
Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
NCT03885830 ·Status: COMPLETED
-
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
NCT05743465 ·Status: COMPLETED
-
TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
NCT01860456 ·Status: COMPLETED
-
Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
NCT00129740 ·Status: COMPLETED ·Phase: PHASE2
-
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
NCT00702403 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
NCT01426334 ·Status: TERMINATED ·Phase: PHASE1
-
Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy
NCT01456676 ·Status: COMPLETED ·Phase: PHASE1
-
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
NCT03045120 ·Status: COMPLETED
-
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
NCT01660906 ·Status: COMPLETED ·Phase: PHASE4
-
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
NCT00816114 ·Status: RECRUITING
-
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT04329325 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
NCT00254423 ·Status: COMPLETED ·Phase: PHASE2
-
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
NCT02709083 ·Status: TERMINATED ·Phase: PHASE2
-
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
NCT01498445 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib
NCT01223898 ·Status: COMPLETED ·Phase: PHASE1
-
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00255346 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00022490 ·Status: TERMINATED ·Phase: PHASE2
-
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
NCT05682924 ·Status: RECRUITING
-
Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia
NCT04147533 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
NCT06121765 ·Status: NOT_YET_RECRUITING
-
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
NCT03654768 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
NCT02879695 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase
NCT00481052 ·Status: COMPLETED ·Phase: PHASE2
-
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00015834 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
NCT01593254 ·Status: COMPLETED ·Phase: PHASE2